Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

End points were measured from baseline to week 52. Values are derived from an analysis of variance for the treatment policy estimand (top part of table) and a mixed-model-for-repeated-measures ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...

Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents ...

Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...